Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

AcelRx Pharmaceuticals

Jaguar Health

ReShape Lifesciences

Tellurian

Analysts say these are penny stocks to buy. Do you agree?

5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021

BUFFALO, N.Y., Aug. 17, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced that its Chief Executive Officer, James A. Mish, is scheduled to present at the SNN Network Summer Virtual Event investor conference on Thursday, August 19, 2021 at 2:30 p.m. ET.

22nd Century to Present at SNN Network Investor Conference on August 19

BUFFALO, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (formerly NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, announced today that it will ring the Nasdaq Closing Bell today, August 16, 2021, in celebration of the transfer of its stock listing to the Nasdaq Capital Market from the NYSE American. The company's common stock begins trading today at the market open under the same ticker symbol “XXII.”

22nd Century Group to Ring Nasdaq Closing Bell Today, August 16

Clever Leaves Holdings Inc

Only focusing on the industry's headliners means you'll miss out on some great opportunities.

3 Under-the-Radar Cannabis Stocks Investors Need to Know

BUFFALO, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, announced today that its common stock has been approved for uplisting to the Nasdaq Capital Market effective as of the market open on August 16, 2021. The shares will continue to trade under the ticker symbol “XXII.”

22nd Century Group to Begin Trading on Nasdaq on August 16, 2021

22nd Century Group, Inc. (XXII) CEO Jim Mish on Q2 2021 Results - Earnings Call Transcript

BUFFALO, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII ), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today reported results for the second quarter ended June 30, 2021, and provided an update on recent business highlights. The Company will provide an additional business update for investors on a live audio webcast to be held today at 10:00 a.m. ET.

22nd Century Group Reports Business Highlights and Financial Results for the Second Quarter 2021

22nd Century (XXII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will 22nd Century Group (XXII) Report Negative Q2 Earnings? What You Should Know

Company will Increase Investment in Tobacco Production and Testing Equipment and Add New Talent in Preparation for Projected Demand Company will Increase Investment in Tobacco Production and Testing Equipment and Add New Talent in Preparation for Projected Demand

22nd Century Group Secures New Contract Manufacturing Agreements, Expands Distribution Network and Manufacturing Capabilities Ahead of VLN® Launch

BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, will host a live webcast on Thursday, August 5, 2021, at 10:00 AM ET to discuss its 2021 second quarter results. 22nd Century will report the Company's second quarter 2021 results in a press release at 6:00 AM ET the same day.

22nd Century Group to Host Webcast to Provide Business Update and Discuss Second Quarter 2021 Results

Aurora Cannabis

Greenlane Holdings

High Tide

Akerna Corp

Neptune Wellness Solutions Inc.

Tilray Brands

OrganiGram Holdings Inc.

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

Smoking Hot Cannabis Stocks Making Moves Right Now

BUFFALO, N.Y., July 14, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced that it has added strategic partnerships with expert commercial-scale plant breeders Sawatch Agriculture and Folium Botanical. The partnerships with these two northern hemisphere breeders add to the breeding capabilities that 22nd Century already has through its close partnership with Aurora Cannabis, and another southern hemisphere-based breeder that will be announced shortly, providing 22nd Century year-round growing capabilities.

22nd Century Group Adds Strategic Partnerships With Sawatch Agriculture and Folium Botanical for Next-Generation Commercial Hemp/Cannabis Plant Breeding and Commercial Scale-Up

Alto Ingredients

DAVIDsTEA

Enthusiast Gaming Holdings

1847 GOEDEKER INC.

NGL Energy Partners

ReneSola

Reddit's retail crowd may buy these seven penny stocks whose sound business fundamentals and relative under-valuation will close the gap for tremendous upside. The post 7 Reddit Penny Stocks for Your July Buy List appeared first on InvestorPlace.

7 Reddit Penny Stocks for Your July Buy List

GrowGeneration Corp

HEXO Corp

Coffee Holding

Village Farms International

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry continues to shape up in 2021.

Pot Stock Roundup: Apple Enters the Fray

22nd Century Takes Ownership of Needle Rock Farms, Provides North American Cultivation Base of Operations 22nd Century Takes Ownership of Needle Rock Farms, Provides North American Cultivation Base of Operations

22nd Century Announces Restructuring of Panacea Investment, Expansion of Cannabis Franchise Capabilities

The company gives investors exposure to three different markets.

Is 22nd Century Group a Buy?

BUFFALO, N.Y., June 25, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today released an update letter to its shareholders from CEO James A. Mish.

22nd Century Group Provides Business Update from CEO Detailing Company Progress Over Past Year and Future Initiatives

Bionano Genomics

BioNTech SE

Avid Bioservices

Moderna

VistaGen Therapeutics

BioCryst Pharmaceuticals

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.

7 A-Rated Biotech Stocks to Buy Now

Arena Pharmaceuticals

Canopy Growth

Cardiff Oncology

Cronos Group

Hawaiian Electric Industries

Innovative Industrial Properties

Zynerba Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Smoked! How the Hottest Cannabis Stocks Fared This Week

Plant-based biotech company 22nd Century Group, Inc. (AMEX:XXII) has raised $40 million through a previously announced registered direct offering of its 10 million common shares at $4.00 per share. The Buffalo, New York-based company closed the offering on Wednesday.

22nd Century Group Closes Registered Direct Offering, Raises $40M

Financing Provides Support to the Company's Strategic Objectives Across All Its Plant Franchises. Financing Provides Support to the Company's Strategic Objectives Across All Its Plant Franchises.

22nd Century Announces Closing of $40 Million Common Stock Registered Direct Offering

BUFFALO, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, is pleased to announce that it will be added to the Russell 2000®, Russell 3000®, and Russell Global Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.

Reduced Nicotine Tobacco and Cannabinoid Innovator 22nd Century Group to Be Added to Russell 2000®, Russell 3000®, and Russell Global Indexes

Two cannabis companies team up to explore new forms of cannabis consumption.

Why 22nd Century Group, HEXO, and Canopy Growth Stocks All Popped Today

Plant-based biotech company 22nd Century Group, Inc. (NYSE AMEX: XXII) announced Monday it will raise $40 million via a registered direct offering with one institutional investor. The Buffalo, New York-based company involved in cannabis and hemp research agreed to sell 10 million common shares with a price of $4.00 per share.

Shares of 22nd Century Group's Cannabis Research Co. Slightly Up On $40M Registered Direct Offering With Cowen and Company

BUFFALO, N.Y., June 07, 2021 (GLOBE NEWSWIRE) --  22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced new initiatives to strengthen and maximize revenue opportunities in its hemp/cannabis franchise. Included in these developments is the announcement of strategic partnerships with two plant breeders in the northern and southern hemispheres providing the Company with year-round growing capabilities, close partnership activities being conducted with Aurora Cannabis, and the establishment of a newly created Canadian subsidiary. These newest developments further support 22nd Century's plans for multiple avenues of hemp/cannabis revenue that will begin to be realized in late 2021.

News for 22nd Century Group Stock (XXII)